PRDX6 and melanoma: Although PRDX6, MAGOHB, NUCKS1, DCAF13, and TXN genes as a panel displayed weak prediction of ICB response, the panel robustly stratified overall survival in patients with melanoma treated with anti-PD1 following progression on anti-CTLA4 therapy (Figure S4B,C).